Arizona State University Researchers Develop Fast TB Testing Technology to Improve Tuberculosis Treatment in the USA
Tuberculosis (TB) remains one of the most severe infectious disease threats globally, but cutting-edge health research in the USA is paving the way for significant clinical improvements. At Arizona State University, a team of scientists is addressing a critical bottleneck in patient care: the time it takes to determine if a specific strain of TB will respond to standard medications. By developing advanced fast TB testing methods, ASU researchers are providing clinicians with the tools they need to administer targeted, effective tuberculosis treatment immediately.
Explore our related articles for further reading on infectious disease research.
The Persistent Threat of Tuberculosis in the USA and Globally
Despite the widespread belief that tuberculosis is a disease of the past, it continues to cause immense suffering worldwide. According to global health data, TB causes over 10 million illnesses and 1.5 million deaths annually. While the burden is highest in developing nations, the disease remains a tangible threat within the USA. As Shelley Haydel, an infectious disease researcher at Arizona State University, points out, recent localized outbreaks demonstrate that TB can spread rapidly in modern environments. A large outbreak in the Kansas City area, for example, resulted in 68 active cases of infectious TB disease, two deaths, and over 650 people requiring evaluation or monitoring during the investigation.
This outbreak underscores a stark reality: TB anywhere is a threat to people everywhere. The highly contagious nature of the airborne bacteria means that delayed diagnosis or improper tuberculosis treatment can quickly lead to community-wide public health emergencies. Preventing these outbreaks relies entirely on early detection and the immediate deployment of the correct therapeutic protocols.
Understanding Multidrug-Resistant TB
The challenge of controlling TB has been complicated by the evolution of the bacteria itself. In the mid-1900s, scientists developed powerful antibiotics that effectively cured the disease. However, over decades of use, new strains of TB have evolved to resist these drugs. Multidrug-resistant TB (MDR-TB) is a strain that resists at least two of the most effective first-line treatments. The statistics surrounding MDR-TB are alarming; nearly 20% of patients diagnosed with multidrug-resistant TB die within the first year of starting treatment. This high mortality rate is often directly tied to the delay in identifying which drugs the bacteria will respond to, leaving patients on ineffective medications while the disease progresses.
The Challenge of Traditional Drug Susceptibility Testing
Effective tuberculosis treatment requires doctors to perform drug susceptibility testing, a process that determines exactly which antibiotics will kill a patient’s specific strain of TB. Currently, medical professionals are forced to choose between two flawed testing methodologies, neither of which provides an optimal path for fast TB testing.
Molecular vs. Phenotypic Testing Limitations
The first option is molecular testing. This method analyzes the DNA of the TB bacteria to look for specific genetic mutations known to cause drug resistance. The primary advantage of molecular testing is speed; results can often be obtained in a matter of hours. However, its major limitation is its scope. Molecular tests can only look for known genetic markers. When it comes to new, repurposed, or experimental TB drugs, the genetic mutations that cause resistance to these specific medications have not yet been mapped. Therefore, molecular testing cannot tell a doctor if a patient’s TB will resist a newly introduced medication.
The second option is phenotypic testing. This method involves taking a sample of the patient’s TB bacteria and physically growing it in a laboratory environment in the presence of various antibiotics. If the bacteria grow despite the presence of a drug, it is deemed resistant. Phenotypic testing is highly accurate and can test resistance against any drug, including new and experimental ones. The critical drawback is time. Because TB bacteria grow incredibly slowly, phenotypic testing can take weeks to yield results. During this waiting period, doctors are forced to make educated guesses about tuberculosis treatment, often relying on broad-spectrum drugs that may be ineffective, allowing the bacteria to continue damaging the patient’s lungs and potentially spreading to others.
Submit your application today to join cutting-edge health research programs.
Arizona State University’s Approach to Fast TB Testing
Recognizing the critical need for a solution that combines the breadth of phenotypic testing with the speed of molecular testing, Arizona State University researchers Shelley Haydel and Shaopeng Wang have launched an ambitious project. Funded by a $2.3 million grant from the National Institute of Allergy and Infectious Diseases, their work focuses on fundamentally changing how laboratories conduct drug susceptibility testing.
Haydel and Wang bring together highly specialized expertise from multiple disciplines at ASU. Both are faculty members in the Biodesign Center for Bioelectronics and Biosensors. Additionally, Haydel is a professor in the School of Life Sciences, while Wang is an associate professor in the John Shufeldt School of Medicine and Medical Engineering and the School of Biological and Health Systems Engineering. This cross-disciplinary collaboration is a hallmark of modern health research in the USA, combining deep biological knowledge with advanced engineering principles.
Integrating Optical Imaging with Deep Learning
The core innovation proposed by the ASU team relies on a sophisticated combination of scattering-based optical imaging and advanced deep learning algorithms. Instead of waiting for visible bacterial colonies to grow over several weeks, this new technology uses highly sensitive optical techniques to detect microscopic changes in the bacteria at a much earlier stage.
When TB bacteria are exposed to an antibiotic, the drug begins to affect the cellular structure and metabolism of the organism long before the cell actually dies or stops dividing. Scattering-based optical imaging can capture these minute physical changes by analyzing how light interacts with the bacterial cells. However, the data generated by these optical scans is incredibly complex and difficult for a human technician to interpret manually.
To solve this, the researchers employ deep learning, a subset of artificial intelligence that excels at pattern recognition. By training the deep learning models on thousands of images of TB bacteria responding to various drugs, the system learns to identify the specific optical signatures that indicate a drug is working—or failing to work. This allows the technology to rapidly and accurately determine TB drug susceptibility in a fraction of the time required by traditional phenotypic testing.
This approach effectively bridges the gap in current fast TB testing. It provides the comprehensive drug coverage of a phenotypic test—meaning it can evaluate new, repurposed, and experimental drugs—while drastically reducing the time required to get those results into the hands of prescribing physicians.
The Future of Tuberculosis Treatment and Health Research
The implications of this technology for tuberculosis treatment are profound. When doctors can quickly and accurately identify the exact drug resistance profile of a patient’s TB strain, they can immediately prescribe the most effective medication regimen. This targeted approach increases the chances of a full recovery, reduces the severe side effects associated with taking ineffective drugs, and limits the further transmission of the disease.
Furthermore, this technology has the potential to accelerate health research related to new TB drugs. Pharmaceutical companies and researchers developing new antibiotics often struggle to quickly assess the efficacy of their compounds. A rapid, universal drug susceptibility testing platform would allow for faster clinical trials and quicker deployment of new life-saving treatments to the market.
The work being done at Arizona State University serves as a prime example of how targeted investments in health research in the USA can yield practical solutions to global health crises. By aligning infectious disease expertise with cutting-edge medical engineering and bioelectronics, ASU is addressing the root causes of treatment failure. As drug-resistant strains of TB continue to emerge, the demand for fast, accurate, and adaptable testing will only increase. The development of optical imaging combined with deep learning represents a significant step forward in ensuring that tuberculosis treatment keeps pace with the evolving threat of the disease.
Have questions about the future of medical diagnostics? Write to us!
